Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

K Pharma,Inc. (4896) Stock Price & Analysis

0 Followers

4896 Stock Chart & Stats

¥678.00¥21.00(10.24%)
At close: 3:30 PM GMT+9
¥600¥700¥800Aug 17Aug 31Sep 14Sep 28Oct 13Oct 26Nov 9
Day’s Range
JPY 660.00 - JPY 678.00
52-Week Range
JPY 611.00 - JPY 949.00
Previous Close
JPY 615.00
Volume
N/A
Average Volume (3M)
25.98K
Market Cap
JPY 7.15B
Enterprise Value
JPY 7.25B
Total Cash (Recent Filing)
JPY 2.71B
Total Debt (Recent Filing)
JPY 1.65B
Price to Earnings (P/E)
―
Beta
0.87
Next Earnings
Nov 13, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Prior Profitability

The 2023 results show that the company has previously generated meaningful revenue and positive net income. Although this performance has not continued, that history provides evidence of potential commercial execution and a possible foundation for restoring earnings if operations recover.

Improving Cash Burn

The modest reduction in cash burn is a constructive direction in financial performance, even though cash flow remains negative. Continued improvement could extend the company’s operating runway and reduce the pace at which it must seek external funding.

Existing Asset Base

Maintaining approximately ¥2.94B of total assets gives the company an established balance-sheet resource base from which to support development activities. This does not remove funding pressure, but it provides more operating substance than a business with minimal remaining assets.

Bears Say

Zero Revenue And Large Losses

The disappearance of reported revenue alongside large operating and net losses is the clearest fundamental weakness. Without renewed commercial revenue, the company lacks an operating engine to absorb R&D and other costs, making a durable return to profitability difficult to establish.

Persistent Cash Burn

Sustained negative operating and free cash flow means the business is consuming cash rather than funding itself. Unless revenue returns or spending falls materially, ongoing losses can require additional financing and leave fewer resources available for development and growth.

Shrinking Equity And Higher Leverage

The combination of a sharply smaller equity base and higher debt weakens financial flexibility. Rising leverage increases the importance of future funding or operational recovery, while continued losses could further erode capital and constrain investment in the business.

4896 FAQ

What was K Pharma,Inc.’s price range in the past 12 months?
K Pharma,Inc. lowest stock price was ¥611.00 and its highest was ¥949.00 in the past 12 months.
What is K Pharma,Inc.’s market cap?
K Pharma,Inc.’s market cap is ¥7.15B.
When is K Pharma,Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were K Pharma,Inc.’s earnings last quarter?
K Pharma,Inc. released its earnings results on Aug 13, 2026. The company reported -¥20.84 earnings per share for the quarter.
Is K Pharma,Inc. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does K Pharma,Inc. pay dividends?
K Pharma,Inc. does not currently pay dividends.
What is K Pharma,Inc.’s EPS estimate?
K Pharma,Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does K Pharma,Inc. have?
K Pharma,Inc. has 11,622,600 shares outstanding.
What happened to K Pharma,Inc.’s price movement after its last earnings report?
K Pharma,Inc. reported an EPS of -¥20.84 in its last earnings report. Following the earnings report the stock price went up 2.937%.
Which hedge fund is a major shareholder of K Pharma,Inc.?
Currently, no hedge funds are holding shares in JP:4896
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology